Ayrton Drugs Manufacturing Company Ltd. Stock

Equities

AYRTN

GH0000000672

Pharmaceuticals

End-of-day quote Ghana S.E.
- GHS - Intraday chart for Ayrton Drugs Manufacturing Company Ltd.
Sales 2016 38.77M 2.87M Sales 2017 35.02M 2.59M Capitalization 21.5M 1.59M
Net income 2016 2M 148K Net income 2017 2M 148K EV / Sales 2016 0.79 x
Net Debt 2016 4.81M 356K Net Debt 2017 6.12M 453K EV / Sales 2017 0.79 x
P/E ratio 2016
9.93 x
P/E ratio 2017
9.41 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 59.36%
More Fundamentals * Assessed data
Ayrton Drug Manufacturing Ltd Reports Earnings Results for the First Quarter Ended September 30, 2019 CI
Ayrton Drug Manufacturing Ltd Reports Earnings Results for the Full Year Ended June 30, 2019 CI
Ayrton Drug Manufacturing Ltd Reports Earnings Results for the Half Year Ended December 31, 2018 CI
Ayrton Drugs Manufacturing Company Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2018 CI
Ayrton Drug Manufacturing Ltd Announces Unaudited Earnings Results for the Period Ending June 30, 2018 CI
Ayrton Drugs Manufacturing Company Ltd. Reports Unaudited Financial Results for the Third Quarter Ended March 31, 2018 CI
Ayrton Drug Manufacturing Ltd. Announces Unaudited Earnings Results for the First Quarter Ended Sep. 30, 2017 CI
Ayrton Drug Manufacturing Ltd Announces Unaudited Earnings Results for the Third Quarter Ended March 31, 2017 CI
Ayrton Drugs Manufacturing Limited Reports Unaudited Earnings Results for the Half Year Ended December 31, 2016 CI
Dannex Limited completed the acquisition of 53.47% stake in Ayrton Drugs Manufacturing Company Ltd. from Adcock Ingram Holdings Limited. CI
Ayrton Drugs Manufacturing Limited Reports Earnings Results for the Year Ended June 30, 2016 CI
Dannex Plans To Acquire 53.47% Stake In Ayrton CI
Dannex Limited entered into a sale of shares agreement to acquire 53.47% stake in Ayrton Drugs Manufacturing Company Ltd. from Adcock Ingram Holdings Limited. CI
Ayrton Drugs Manufacturing Limited Announces Unaudited Earnings Results for the Third Quarter Ended March 31, 2016 CI
Adcock Ingram To Divest Ayrton Drugs And Indian Sales & Marketing Unit CI
More news
Ayrton Drug Manufacturing Company Limited manufactures, imports and supplies pharmaceutical products in West Africa. The Company offers various products, including Antitussives, such as Samalin Adult, Samalin Junior and Samalin Non-Drowsy Junior; Apetite stimulants and vitamin, such as Ayrton Multivitamin Syrup, and Heptamin Syrup and Capsules; Anti-Hypertensives, such as Adco-Atenolol; Blood and Iron Tonics, such as Virol Blood Tonic and Haemoglobin Syrup; Dermatological, such as Clobet Triple Action and Clofen Gel; Anti-Allergy, such as Allergex and Allergex Elixir; Antacid, such as Res Q Tablets and Syrups; Anti-Diarrohoea, such as Adco-Loperamide tablets; Analgesics/Antipyretics/Non-steriodal, such as Baby Paralex, Panacin and Paracetamol Tablet; Anti-bacterial, such as Amoxycillin and Cotrimoxazole Tablets, and Antiprotozoal, such as Metronidazole Suspension.
More about the company